Top

Cancer Chemotherapy and Pharmacology

Published in:

01-10-2020 | Neutropenia | Original Article

Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer

Authors: Takahiro Tsushima, Hidefumi Kasai, Yusuke Tanigawara

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2020

Abstract

Purpose

To develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for neutropenia following nab-paclitaxel administration and identify factors associated with drug disposition and changes in neutrophil counts in patients with solid cancer.

Methods

PK/PD analysis by nonlinear mixed effects approach was performed using the data from 27 patients who participated in phase I studies of nab-paclitaxel monotherapy conducted in Japan. The patients were treated with either weekly (80, 100, or 125 mg/m²) or every 3 weeks (200, 260, or 300 mg/m²). The observed paclitaxel concentrations in whole blood and neutrophil counts in the first cycle were used for PK/PD analysis. Covariate analysis was performed to identify factors affecting PK and the decrease in neutrophil counts.

Results

The developed 3-compartment, non-linear PK model described relationships of body surface area with total body clearance and volume of distribution for the peripheral compartment. Covariate factors affecting neutrophil counts were age and serum albumin level. Simulation based on the developed PK/PD model showed a substantial impact of age and serum albumin level on the time course of neutrophil counts after nab-paclitaxel administration. Advanced age was related to greater decrease in neutrophil counts, and serum albumin level, inversely related to change in neutrophil counts.

Conclusion

We have developed a novel PK/PD model for nab-paclitaxel in which age and serum albumin level were considered clinically important covariate factors. This model needs to be further validated using a larger patient population.

Available only for authorised users

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263–1268. https://doi.org/10.1200/JCO.1990.8.7.1263CrossRefPubMed

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. https://doi.org/10.1200/JCO.2005.04.937CrossRefPubMed

Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W (2017) Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2(4):277–287. https://doi.org/10.1016/S2468-1253(16)30219-9CrossRefPubMed

Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T (2010) Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 40(5):404–411. https://doi.org/10.1093/jjco/hyp192CrossRefPubMedPubMedCentral

Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y (2012) Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 69(2):457–465. https://doi.org/10.1007/s00280-011-1726-5CrossRefPubMed

Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558–569. https://doi.org/10.1208/s12248-009-9133-0CrossRefPubMedPubMedCentral

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713–4721. https://doi.org/10.1200/JCO.2002.02.140CrossRefPubMed

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143–151. https://doi.org/10.1208/s12248-011-9255-zCrossRefPubMedPubMedCentral

Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190. https://doi.org/10.1200/JCO.1995.13.1.180CrossRefPubMed

10.

Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14(13):4200–4205. https://doi.org/10.1158/1078-0432.CCR-07-4592CrossRefPubMedPubMedCentral

11.

Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465. https://doi.org/10.1200/JCO.2011.34.7625CrossRefPubMedPubMedCentral

12.

Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM (2013) Toxicity of initial chemotherapy in older patients with lung cancers. J Geriatr Oncol 4(1):64–70. https://doi.org/10.1016/j.jgo.2012.09.003CrossRefPubMed

13.

Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24(25):4085–4091. https://doi.org/10.1200/JCO.2006.06.9039CrossRefPubMed

14.

Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54(10):1097–1107. https://doi.org/10.1002/jcph.304CrossRefPubMedPubMedCentral

15.

Ballmer PE, Ochsenbein AF, Schutz-Hofmann S (1994) Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 43(6):697–705. https://doi.org/10.1016/0026-0495(94)90117-1CrossRefPubMed

16.

Yeun JY, Kaysen GA (1998) Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32(6 Suppl 4):S118–125. https://doi.org/10.1016/s0272-6386(98)70174-xCrossRefPubMed

17.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. https://doi.org/10.1038/nature07205CrossRefPubMed

18.

Dumitru CA, Lang S, Brandau S (2013) Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 23(3):141–148. https://doi.org/10.1016/j.semcancer.2013.02.005CrossRefPubMed

19.

Ishizuka M, Nagata H, Takagi K, Kubota K (2009) Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg 250(2):268–272. https://doi.org/10.1097/SLA.0b013e3181b16e24CrossRefPubMed

20.

Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N (2004) Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 48(2):171–173. https://doi.org/10.1207/s15327914nc4802_6CrossRefPubMed

21.

Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang HW, Fang FM, Huang YJ (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92(2):270–275. https://doi.org/10.1016/j.radonc.2009.01.002CrossRefPubMed

22.

Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19(20):4065–4073. https://doi.org/10.1200/JCO.2001.19.20.4065CrossRefPubMed

23.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J (2003) Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 21(2):197–202. https://doi.org/10.1200/JCO.2003.01.058CrossRefPubMed

Title: Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer
Authors: Takahiro Tsushima
Hidefumi Kasai
Yusuke Tanigawara
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keyword: Neutropenia
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2020
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04140-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction

Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer